Ivabradine Reduces Digitalis-induced Ventricular Arrhythmias (Q38719493)

5 September 2017

title

Ivabradine Reduces Digitalis-induced Ventricular Arrhythmias (English)

1 reference

5 September 2017

9

Lars Eckardt

1 reference

5 September 2017

8

Kristina Wasmer

1 reference

5 September 2017

4

Nils Bögeholz

1 reference

5 September 2017

1

Gerrit Frommeyer

1 reference

5 September 2017

7

Simon Kochhäuser

1 reference

5 September 2017

Jan Weller

2

1 reference

5 September 2017

Christian Ellermann

series ordinal

3

1 reference

5 September 2017

Patrick Leitz

series ordinal

5

1 reference

5 September 2017

Dirk G Dechering

series ordinal

6

1 reference

5 September 2017

publication date

19 June 2017

1 reference

Basic and Clinical Pharmacology and Toxicology

5 September 2017

published in

1 reference

The inotropic effect of cardioactive glycosides in ventricular myocytes requires Na -Ca2 exchanger function

5 September 2017

cites work

1 reference

Dronedarone and digitalis: individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias

21 January 2018

1 reference

Interactions of digitalis and class-III antiarrhythmic drugs: Amiodarone versus dronedarone

21 January 2018

1 reference

Interaction between digoxin and dronedarone in the PALLAS trial

21 January 2018

1 reference

The heart rate-lowering agent ivabradine inhibits the pacemaker current I(f) in human atrial myocytes

21 January 2018

1 reference

hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine

21 January 2018

1 reference

Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4.

21 January 2018

1 reference

If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation.

21 January 2018

1 reference

Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation

21 January 2018

1 reference

Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation

21 January 2018

1 reference

A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase‐III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing‐induced heart failure

21 January 2018

1 reference

Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects

21 January 2018

1 reference

Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome

21 January 2018

1 reference

Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome

21 January 2018

1 reference

Vernakalant in an experimental model of pacing-induced heart failure: lack of proarrhythmia despite prolongation of repolarization

21 January 2018

1 reference

Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization

21 January 2018

1 reference

Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?

21 January 2018

1 reference

Ivabradine: Current and Future Treatment of Heart Failure.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BCPT.12829

1 reference

5 September 2017

1 reference